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Right Time for Each IndividualValentin Fuster, MD, PHDO ver the past 20 years, a plethora of newhealth care delivery models have been pro-posed, including personalized medicine,
precision medicine, patient-centered medical home,
and accountable care organizations—many of which
have been recommended by policy makers or politi-
cians. When we are trying to establish goals toward
improved cardiovascular health or promoting health
on a population-wide scale, it is important to re-
member that we need unique strategies at different
stages of our lives, depending on the varied scienti-
ﬁc/physiopathological background and educational/
behavioral tools appropriate for each stage.
Over the past year, within these Editor’s Pages, I
have discussed 3 historical challenges affecting car-
diovascular medicine: 1) poor medication adherence,
which thwarts efforts to develop improved, person-
alized treatments proven so effective in oncology (1);
2) the need to emphasize to young doctors how
critical and signiﬁcant the personal interaction is
between the physician and his or her patient (2); and
3) a main barrier to health promotion that I
have witnessed on a global or population-wide scale:
a shocking lack of follow-up or surveillance of the
recommendations made in approximately 30 of the
clinical/governmental documents created in the last 2
decades (3). As an example of a positive alternative to
such a lack of follow-up, the U.S. Institute of Medi-
cine (IOM) formed a committee, for which I served as
the chair, with the objective to create a set of tangible
recommendations that would catalyze and focus
action around the burgeoning global epidemic of
noncommunicable diseases in the developing world.
The resulting 2010 report, “Promoting Cardiovascular. Wiener Cardiovascular Institute, Icahn
inai, New York, New York.Health in the Developing World” (4), proposed 12
feasible strategies, including a strict monitoring plan
for each strategy and a follow-up of the results. When
we formed the IOM committee, this group of physi-
cians, economists, and governmental representatives
all recognized the need to follow-up on our recom-
mendations; in fact, our 12 recommendations actually
prescribed a model to report on global progress using
the World Health Organization monitoring model.
Charting progress in a consistent, standardized way is
integral to moving ahead. To ensure appropriate
follow-up with our IOM recommendations, we re-
cently published a comprehensive evaluation of each
recommendation in a special issue of Scientiﬁc
American (5).
Because signiﬁcant challenges exist in health
promotion, let us look toward the future. First of all,
the National Heart, Lung, and Blood Institute has
established human health as a top strategic vision for
the future (6), in contrast to a complete focus on
disease. As such, this issue of health remains in the
forefront for many clinicians and national organiza-
tions, not only because of the clinical “burden” of
disease, but also because of the economic “burden”
that cardiovascular diseases place in our society
(Figure 1). Accordingly, we would like to propose a
strategy for sustaining health throughout a lifetime,
which involves a stratiﬁed approach at 3 different age
ranges in the life of an individual that could be most
effective in promoting cardiovascular health or pre-
venting the progression of disease—even among those
at highest risk for cardiovascular events. This strategy
cannot be employed in the same way at the same
time for every individual, because the scientiﬁc/
physiopathological background and educational/
behavioral tools available vary at different stages in
time. As we will outline, these are strategies per-
taining to health promotion that my colleagues and
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1628I have learned through recent studies and trials across
the globe (Figure 1).
As the ﬁrst approach to stratiﬁed health is within the
ﬁrst 25 years of life, it is reasonable to assume that at
that stage there is no signiﬁcant cardiovascular dis-
ease yet. We have learned that the optimal period of
time tomotivate behavior in favor of health is between
the age of 3 to 5 years. Indeed, there is evolving evi-
dence that our behavior as adults has its roots in the
environment that we live in from age 3 to 5 years.
Furthermore, unhealthy diets begin to inﬂuence
cardiovascular disease markers early in life, and
conditions such dyslipidemia, high blood pressure,
impaired glucose tolerance, as well as obesity and
metabolic syndrome may become rooted as early as 3
to 5 years of age, increasing the risk of development of
atherosclerosis in adolescence and early adulthood
(7–9). During these ages, education can include such
topics as how the body and heart work, healthy food
habits, physical activity, and emotional habits to avoid
addictions. In the SI! Program for Cardiovascular
Health Promotion in Early Childhood, for example, the
intervention was designed to be applied at all pre-
school levels in 24 Madrid, Spain, schools, including
2,062 children age 3 to 5 years, for the purpose of
promoting cardiovascular health among children us-
ing their proximal environment (school, teachers, and
families). Children were therefore exposed for 3 years,
2 years, or 1 year, depending on their starting grade.Improvement was initially demonstrated during the
ﬁrst year of intervention (10). This program translated
into a beneﬁcial effect on adiposity, with maximal ef-
fect when started at the earliest age and maintained
over 3 years (7). The results presented in the Madrid
SI! Program align well with those obtained previously
by our Colombian Initiative (11,12). After the inter-
vention, Colombian preschoolers were followed-up
for 36 months, sustaining the effect toward healthier
behaviors (12) and ultimately leading to a nationwide
expansion of the program. The critical question will be
answeredwhen these children are 15 to 20 years of age.
In other words, can the intervention at age 3 to 5 years
affect health behaviors when these children reach
adulthood?
As the second opportunity for stratiﬁed health, the
age range of 25 to 50 years appears to be the right time
to evaluate subclinical disease, about which we have
been learning a signiﬁcant amount through non-
invasive imaging techniques. In 2 recent bioimaging
studies, we assessed approximately 10,000 asymp-
tomatic adults >40 years of age using multimodality
vascular imaging of the coronary arteries with
electron-beam computed tomography for calciﬁca-
tion and of the carotid arteries with 3-dimensional
ultrasound. We found that subclinical atheroscle-
rosis was highly prevalent, detectable in both the
coronary and carotid vascular territories (more
recently also in the iloi-femoral region) in close to
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162960% of participants (13,14). Thus, we concluded that
incorporating detection of subclinical atherosclerosis
irrespective of anatomic territory, in addition to
cardiovascular risk factors, would motivate patients
to change their lifestyle. Through the use of advanced
imaging technologies, we are now testing, in such
adult populations with manifested subclinical dis-
ease, whether addressing risk factor proﬁle through
“group therapy” or an intensiﬁed and “around-the-
clock” personalized approach is of more beneﬁt in
terms of changing life-style and preventing progres-
sion of the disease than the usual conventional
means.
The third opportunity for stratiﬁed health is for
individuals age 50 years onward, when cardiovas-
cular disease has often begun to manifest itself
symptomatically or by an adverse event. It is of value
to approach this population by taking into account
the total body vasculatures, including the heart and
the brain. Thus, it has been increasingly recognized
that degenerative brain disease is intimately linked to
the vasculature and overall burden of atherosclerosis
disease (15,16). Speciﬁcally, the heart–degenerative
brain disease axis is perceptible across a very broad
spectrum of disease, from macrovascular large-vessel
coronary, carotid, or ilio-femoral diseases leading tomyocardial infarction or stroke, to microvascular
small vessel changes causing dementia. Thus, we
must make a transition from primarily considering
the coronary vessels to looking at the entire individ-
ual in terms of systemic cardiovascular disease, which
includes the neurovascular region. Furthermore, in
the elderly population with already manifested dis-
ease, 2 pharmacological challenges need to be
addressed: 1) can adherence to medication be
improved (17); and 2) can medication be simpliﬁed
such as with the use of a polypill (18)?
In summary, at every age range, there are speci-
ﬁc scientiﬁc/physiopathological backgrounds and
educational/behavioral tools available to best inter-
vene. Although there have been external pressures to
make “medicine” more personalized or precision-
based—terms that have yet to be clearly deﬁned—
those of us who are actually entrusted to keep people
healthy need to start approaching the population
with a stratiﬁed health strategy.
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